1. Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel M. Davis Blood Volume 126(1):50-60 July 2, 2015 ©2015 by American Society of Hematology

2. Lenalidomide treatment increases IFN-γ secretion from NK cells. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

3. Lenalidomide increases the proportion of pNK cells expressing IFN-γ as well as the amount produced per cell. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

4. Lenalidomide lowers the threshold for NK-cell activation through NKG2D and CD16. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

5. Lenalidomide treatment augments opening of cortical actin mesh after CD16 stimulation. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

6. Lenalidomide treatment augments opening of cortical actin mesh after NKG2D and LFA-1 ligation. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

7. Lenalidomide treatment increases NK-cell activation through rituximab. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

8. Lenalidomide augments NK-cell IFN-γ production and cortical actin rearrangements in NK cells isolated from MM patients. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology